Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Minocycline as Adjunctive Treatment for Treatment Resistant Depression
NCT03947827Phase 3Completed
- Sponsor
- Center for Addiction and Mental Health
- Start
- Feb 2020
- Primary completion
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in treatment-resistant depression (TRD) comparing Active (Minocycline + TAU) with Placebo + TAU (2 arms). Primary endpoint: Hamilton Depression Rating Scale at 12 weeks. Started Feb 2020; status: completed.
02
Drugs
minocycline
03
Conditions
treatment-resistant depression (TRD)
Beyond the preview
Go deeper on NCT03947827.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03947827.